Fig. 4
From: Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter
Role of CAFs-derived FGF7 in ovarian cancer progression. A Concentration of FGF7 in the medium of different cell types quantified using enzyme-linked immunosorbent assay (ELISA). B Cell viability of HO8910 cells measured by CCK8 assay after neutralizing FGF7 in CAFs-CM. C Cell viability of A2780 cells measured by CCK8 assay after neutralizing FGF7 in CAFs-CM. D Cell invasion ability evaluated by Transwell assay after 48 h in HO8910 and A2780 cells (200 × magnification). E Cell viability of HO8910 cells treated with different doses of hFGF7 measured by CCK8 assay. F Cell viability of A2780 cells treated with different doses of hFGF7 measured by CCK8 assay. G Cell invasion ability assessed by Transwell assay after 48 h in HO8910 and A2780 cells treated with different doses of hFGF7 (200 × magnification). H Wound healing assay used to measure cell migration ability after treatment with hFGF7 for 24 h (100 × magnification). I Expression of epithelial-mesenchymal transition (EMT) markers in ovarian cancer (OC) cells treated with different doses of hFGF7 examined by western blotting. Results are presented as the mean ± SD of three independent experiments. ****P < 0.0001, *P < 0.05